apomorphine-paraquinone | 24192-17-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: apomorphine-paraquinone
• 英文别名: 10-hydroxy-6-methyl-5,6-dihydro-4H-dibenzo[de,g]quinoline-8,11-dione；10-Hydroxy-6a,7-dehydro-apomorphinchinon-(8,11)
• CAS: 24192-17-4
• 化学式: C₁₇H₁₃NO₃
• 分子量: 279.295
• InChiKey: BZVNLPISIGKPHZ-UHFFFAOYSA-N

物化性质

• 熔点：
  235 °C
• 沸点：
  583.3±50.0 °C(Predicted)
• 密度：
  1.456±0.06 g/cm3(Predicted)
• 溶解度：
  氯仿（微溶）、甲醇（微溶、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  2.65
• 重原子数：
  21.0
• 可旋转键数：
  0.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  57.61
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  apomorphine hydrochloride 在 sodium hydroxide 、 氧气 作用下， 以 水 为溶剂， 反应 24.0h， 以58%的产率得到apomorphine-paraquinone
  参考文献：
  名称：

  Opposite vascular activity of (R)-apomorphine and its oxidised derivatives. Endothelium-dependent vasoconstriction induced by the auto-oxidation metabolite

  摘要：

  We have synthetised a series of oxidised apomorphine derivatives (orto and para quinones 2-5), in order to analyse their vascular activity. We have performed radioligand binding assays on rat cortical membranes and functional studies on rat aortic rings. Instead the relaxant activity exhibited by (R)-apomorphine, o-quinones 2, 4, show contractile activity dependent on endothelium in rat aortic rings. Compound 2, the main metabolite of (R)-apomorphine auto-oxidation, was the product which showed enhanced contractile activity by a complex mechanism related to activation of Ca(2+) channels through release and/or inhibition of endothelial factors. Moreover, this compound disrupts the endothelial function as shows the lack of response to acetylcholine observed in vessels pretreated with it.

  DOI：

  10.1016/s0223-5234(03)00057-6

文献信息

• RAPIDLY DISINTEGRATING FORMULATIONS AND METHODS OF USE
  申请人：Impax Laboratories, Inc.

  公开号：EP3068396B1

  公开（公告）日：2019-05-08
• RAPIDLY DISINTEGRATING FORMULATIONS AND METHODS THEREOF
  申请人：IMPAX LABORATORIES, INC.

  公开号：US20160296463A1

  公开（公告）日：2016-10-13

  The invention relates to a rapidly disintegrating oral dosage form that contains a drug/polymer solid solution and methods of using the oral dosage form.